Active
Mainboard

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd IPO opened on 20 Dec 2024 and closed on 24 Dec 2024, with a price band of ₹372–₹391 per share. The IPO had a lot size of 38 shares, requiring a minimum investment of ₹14,858 per lot at the upper price band. The issue size was ₹582.11 crore, and the shares get listed on 30 Dec 2024.

Senores Pharmaceuticals Ltd IPO Details

Listing Date

30 Dec 2024

Bid Price

₹372 - ₹391

Lot Size

38 Shares

Minimum Investment

₹14,858 / Lot

Issue Size

₹582.11 Cr

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

20th Dec

tick

Offer End Date

24th Dec

tick

Allotment Date

26th Dec

tick

Refund Initiation

26th Dec

tick

Demat Transfer

27th Dec

tick

Listing Date

30th Dec

Senores Pharmaceuticals Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 66.66% 45.76%
Public Group 33.34% 54.24%

Senores Pharmaceuticals Ltd IPO Reservation

QIB Shares Offered 44,43,817 (29.85%)
NII (HNI) Shares Offered 22,21,909 (14.92%)
Retail Shares Offered 14,81,272 (9.95%)
Anchor Investor Shares Offered 66,65,726 (44.77%)
Total Shares Offered 1,48,87,724
Total Shares With Anchor Investor 1,48,87,724

Senores Pharmaceuticals Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 38 ₹14,858
Retail (Max) 13 494 ₹1,93,154
S HNI (Min) 14 532 ₹2,08,012
S HNI (Max) 67 2,546 ₹9,95,486
B HNI (MIN) 68 2,584 ₹10,10,344

Senores Pharmaceuticals Ltd IPO Anchor Portion Size

Bid Date December 19, 2024

Senores Pharmaceuticals Ltd IPO registrar

MUFG Intime India Pvt Ltd
Phone Number +91 8108114949
Email Id senorespharma.ipo@linkintime.co.in
Website https://in.mpms.mufg.com

Senores Pharmaceuticals Ltd IPO Lead Manager

1. Equirus Capital Pvt Ltd

2. Ambit Pvt Ltd

3. Nuvama Wealth Management Ltd

Senores Pharmaceuticals Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹786.18 Cr ₹204.27 Cr ₹45.5 Cr
Reserves and Surplus ₹740.13 Cr ₹173.76 Cr ₹35.68 Cr
Total Borrowing ₹304.76 Cr ₹248.38 Cr ₹60.76 Cr

Strength of Senores Pharmaceuticals Ltd

  • Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.
  • Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.
  • Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.
  • Presence in the Emerging Markets with a product portfolio, including specialty or complex products.
  • R&D capabilities driving our differentiated portfolio of products.
  • Professional management teams for our diverse business verticals.

Risks Involved

  • The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.
  • The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.
  • Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.
  • The company derives a part of its revenue from few customers. If one or more of such customers choose not to source their requirements from it or to terminate the company contracts or purchase orders, its business, cash flows, financial condition and results of operations may be adversely affected.
  • The company has had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on its business and operations.
  • The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations. There have been instances in the past where the company drugs failed to meet standards prescribed under applicable law and action was taken against it by regulatory authorities.
  • The company derives a major portion of its revenue from its operations in the United States. A reduction in demand for the company products in these regions could adversely affect its business, results of operations, financial conditions and cash flows.
  • Any manufacturing or quality control problems may damage its reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, results of operations and financial condition.
  • Some of its Directors and Promoters may have interest in entities, which are in businesses similar to its and this may result in conflict of interest with it. Further, certain of its Promoter Group, Subsidiaries and Group Companies are in the same line of business as it, which may result in a conflict of interest.
  • The erstwhile statutory auditors of the Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.
stock
Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
UTKAL SPECIALITY INDUSTRIES INDIA LIMITED IPO
icon
Closing Tomorrow
SME IPO
Early Access
Bidding Period
10th Jun 2026 - 6th Jun 2026
Price Range
₹62.0 - 66.0
IPO Size
₹35,00,00,000
  • All
  • MainBoard
  • SME
Bidding Period
11th Jun 2026 - 6th Jun 2026
Price Range
₹120.0 - 127.0
IPO Size
₹70,38,00,000
Bidding Period
12th Jun 2026 - 6th Jun 2026
Price Range
₹98.0 - 103.0
IPO Size
₹54,27,00,000
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
GENXAI ANALYTICS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
5th Jun 2026 - 6th Jun 2026
Price Range
₹110.0 - 116.0
IPO Size
₹54,84,00,000
HEXAGON NUTRITION LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
5th Jun 2026 - 6th Jun 2026
Price Range
₹42.0 - 45.0
IPO Size
₹1,39,00,00,000
UHM VACATION LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
4th Jun 2026 - 6th Jun 2026
Price Range
₹157.0 - 166.0
IPO Size
₹36,02,00,000
VAHH CHEMICALS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
4th Jun 2026 - 6th Jun 2026
Price Range
₹61.0 - 61.0
IPO Size
₹13,00,00,000
Bidding Period
3rd Jun 2026 - 6th Jun 2026
Price Range
₹182.0 - 192.0
IPO Size
₹6,31,00,00,000
LIOTECH INDUSTRIES LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
1st Jun 2026 - 6th Jun 2026
Price Range
₹321.0 - 321.0
IPO Size
₹36,00,00,000
MERRITRONIX LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
1st Jun 2026 - 6th Jun 2026
Price Range
₹141.0 - 149.0
IPO Size
₹70,00,00,000
SMR JEWELS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
26th May 2026 - 6th Jun 2026
Price Range
₹125.0 - 128.0
IPO Size
₹12,54,00,000
AUREATE TRADDE LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
29th May 2026 - 6th Jun 2026
Price Range
₹70.0 - 70.0
IPO Size
₹27,00,00,000
Bidding Period
26th May 2026 - 5th May 2026
Price Range
₹59.0 - 63.0
IPO Size
₹18,00,00,000
HARIKANTA OVERSEAS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
20th May 2026 - 5th May 2026
Price Range
₹86.0 - 91.0
IPO Size
₹24,00,00,000
YAASHVI JEWELLERS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
25th May 2026 - 5th May 2026
Price Range
₹83.0 - 83.0
IPO Size
₹44,00,00,000
M R MANIVENI FOODS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
22nd May 2026 - 5th May 2026
Price Range
₹51.0 - 52.0
IPO Size
₹27,00,00,000
QLINE BIOTECH LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
21st May 2026 - 5th May 2026
Price Range
₹326.0 - 343.0
IPO Size
₹2,14,00,00,000
AUTOFURNISH LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
21st May 2026 - 5th May 2026
Price Range
₹41.0 - 41.0
IPO Size
₹15,00,00,000
Bidding Period
21st May 2026 - 5th May 2026
Price Range
₹132.0 - 139.0
IPO Size
₹52,00,00,000
Bidding Period
20th May 2026 - 5th May 2026
Price Range
₹73.0 - 77.0
IPO Size
₹38,00,00,000
Bidding Period
19th May 2026 - 5th May 2026
Price Range
₹61.0 - 63.0
IPO Size
₹50,15,00,000
NFP SAMPOORNA FOODS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
18th May 2026 - 5th May 2026
Price Range
₹52.0 - 55.0
IPO Size
₹25,00,00,000
RFBL FLEXI PACK LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
12th May 2026 - 5th May 2026
Price Range
₹47.0 - 50.0
IPO Size
₹35,00,00,000
  • All
  • MainBoard
  • SME
MERRITRONIX LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
149.00
Listing Day Close
297.25(99.33%)
SMR JEWELS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
128.00
Listing Day Close
103.05(-19.53%)
AUREATE TRADDE LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
70.00
Listing Day Close
66.50(-4.29%)
Issue Prize
63.00
Listing Day Close
60.57(-3.17%)
HARIKANTA OVERSEAS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
91.00
Listing Day Close
75.77(-16.48%)
YAASHVI JEWELLERS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
83.00
Listing Day Close
87.05(4.82%)
M R MANIVENI FOODS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
52.00
Listing Day Close
41.13(-21.15%)
QLINE BIOTECH LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
343.00
Listing Day Close
474.60(38.48%)
AUTOFURNISH LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
41.00
Listing Day Close
45.15(9.76%)
Issue Prize
139.00
Listing Day Close
115.80(-16.55%)
Issue Prize
77.00
Listing Day Close
124.00(61.04%)
Issue Prize
63.00
Listing Day Close
72.75(15.87%)
NFP SAMPOORNA FOODS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
55.00
Listing Day Close
51.80(-5.45%)
RFBL FLEXI PACK LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
50.00
Listing Day Close
55.10(10.00%)
Issue Prize
43.00
Listing Day Close
56.77(32.56%)
SIMCA ADVERTISING LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
183.00
Listing Day Close
163.80(-10.38%)
BAGMANE PRIME OFFICE REIT IPO
icon
SME IPO
Early Access
Issue Prize
100.00
Listing Day Close
103.66(4.00%)
RECODE STUDIOS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
158.00
Listing Day Close
223.75(41.77%)
Issue Prize
98.00
Listing Day Close
82.30(-16.33%)
Issue Prize
171.00
Listing Day Close
208.40(21.64%)

Frequently Asked Questions

What is Senores Pharmaceuticals Ltd IPO?

Answer Field

Senores Pharmaceuticals Ltd IPO is a Mainboard IPO of 1,48,87,724 equity shares of a face value of ₹10 aggregating up to ₹582.11 Crores. The issue is priced at ₹372 to ₹391 per share. The minimum order quantity is 38 Shares. The IPO opens on December 20, 2024, and closes on December 24, 2024. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Senores Pharmaceuticals Ltd IPO will open?

Answer Field

The Senores Pharmaceuticals Ltd IPO opens on December 20, 2024 and closes on December 24, 2024.

What is the lot size of Senores Pharmaceuticals Ltd?

Answer Field

Senores Pharmaceuticals Ltd lot size is 38 shares, and the minimum amount required is ₹14,858.

How to apply for Senores Pharmaceuticals Ltd IPO?

Answer Field

You can apply in Senores Pharmaceuticals Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

  • Login to Bajaj Broking account App/Website & click on IPO
  • Enter the number of lots and price at which you wish to apply.
  • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
  • You will receive a mandate notification to block funds in your UPI app.
  • Approve the mandate request on your UPI and funds will be blocked.

When is Senores Pharmaceuticals Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Senores Pharmaceuticals Ltd IPO will be done on December 26, 2024, and the allotted shares will be credited to your demat account by December 27, 2024.

When is Senores Pharmaceuticals Ltd IPO listing date?

Answer Field

The Senores Pharmaceuticals Ltd listing date is December 30, 2024.

Who is the registrar of Senores Pharmaceuticals Ltd IPO?

Answer Field

The registrar of Senores Pharmaceuticals Ltd IPO is MUFG Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Equirus Capital Pvt Ltd,Ambit Pvt Ltd,Nuvama Wealth Management Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Senores Pharmaceuticals Ltd IPO?

Answer Field

The fresh issue size is ₹500 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Senores Pharmaceuticals Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 38 shares and ₹14,858 amount.

How can I approve the UPI mandate request for Senores Pharmaceuticals Ltd IPO?

Answer Field

To apply for Senores Pharmaceuticals Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Senores Pharmaceuticals Ltd?

Answer Field

The price of each Senores Pharmaceuticals Ltd share will be ranging in between ₹372 to ₹391 per share.

What is the cut-off time for the UPI mandate for Senores Pharmaceuticals Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 24, 2024.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|